New drug shows promise for diabetes and weight loss in phase 2 trial
NCT ID NCT05110846
First seen Feb 05, 2026 · Last updated May 15, 2026 · Updated 13 times
Summary
This study tested a new medicine called CT-868 in 103 overweight or obese adults with type 2 diabetes. The goal was to see if it could lower blood sugar levels and help with weight loss over 26 weeks. Participants received either the drug or a placebo, and researchers measured changes in a key blood sugar marker (HbA1c) and body weight.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Carmot Clinical Center MX01
Monterrey, Nuevo León, Mexico
-
Carmot Clinical Center MX02
Monterrey, Nuevo León, Mexico
-
Carmot Clinical Center MX03
Mexico City, Mexico
-
Carmot Clinical Center MX04
Guadalajara, Jalisco, Mexico
-
Carmot Clinical Center MX05
Mérida, Yucatán, Mexico
Conditions
Explore the condition pages connected to this study.